Condition: Opioid Induced Respiratory Depression · Chronic Opioid Use · Sponsor: Leiden University Medical Center
n this pharmacokinetic/pharmacodynamic modelling study we will determine the ability of intranasal and intravenous naloxone and intravenous nalmefene to reverse opioid (fentanyl and sufentanil)- induced respiratory depression in healthy volunteers and chronic opioid users to develop dosing recommendations in case of opioid-induced respiratory depression from an opioid overdose in clinical practice and in the out-of-hospital overdose.
This description comes directly from the study's public registry record.
Rutger van der Schrier, MD · +31 (0)71 5299893 · r.m.van_der_schrier@lumc.nl
Albert Dahan, MD PhD · +31 (0)71 5299780 · a.dahan@lumc.nl
Always discuss trial participation with your own doctor first.
| Leiden University Medical Center | Leiden, South Holland, Netherlands | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05338632